Micrus has posted a net income of $3.08m for the first quarter 2011, or $0.17 per diluted share, compared to $2.26m, or $0.14 per diluted share, for the comparable period in 2010.
Operating income was $3.8m for the three months ended June 30, 2010, compared with operating income of $2m for the prior-year period
Micrus said that its products are used by interventional neuroradiologists, interventional neurologists and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke.
Micrus’ proprietary, three-dimensional microcoils anatomically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils.
